Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu S Timofeev

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Radiation Protection Dosimetry|May 31, 2014
Software for evaluation of EPR-dosimetry performanceE A Shishkina, Yu S Timofeev, D V Ivanov
Bulletin of Experimental Biology and Medicine|May 26, 2018
Immunochemical Diagnosis of Multiple MyelomaN V Lyubimova, Yu S Timofeev, V M Abaev, et al.
Klinicheskaia Laboratornaia Diagnostika|October 31, 2022
Biochemical profile of Bence-Jones type multiple myelomaNina Vasilyevna Lyubimova, Yu S Timofeev, V M Abaev, et al.
Bulletin of Experimental Biology and Medicine|March 10, 2020
Glial Fibrillary Acidic Protein in the Diagnosis and Prognosis of Malignant Glial TumorsN V Lyubimova, Yu S Timofeev, A A Mitrofanov, et al.
Bulletin of Experimental Biology and Medicine|August 12, 2014
Components of the RANK/RANKL/OPG system, IL-6, IL-8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumorsN E Kushlinskii, Yu S Timofeev, Yu N Solov'ev, et al.
Bulletin of Experimental Biology and Medicine|June 23, 2022
Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung CancerN V Lyubimova, A E Kuz'minov, A A Markovich, et al.
Klinicheskaia Laboratornaia Diagnostika|September 12, 2022
Chromogranin B in blood serum of patients with neuroendocrine tumorsNina Vasilyevna Lyubimova, Yu S Timofeev, A A Markovich, et al.
Bulletin of Experimental Biology and Medicine|August 31, 2017
Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone TumorsN E Kushlinskii, E S Gershtein, Yu N Solov'ev, et al.
Bulletin of Experimental Biology and Medicine|November 24, 2020
Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone TumorsN E Kushlinskii, A A Alferov, Yu S Timofeev, et al.
Klinicheskaia Laboratornaia Diagnostika|December 10, 2020
Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcomaNikolay Evgenievich Kushlinskii, A A Alferov, I V Boulytcheva, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Radiation Protection Dosimetry|May 31, 2014
Software for evaluation of EPR-dosimetry performanceE A Shishkina, Yu S Timofeev, D V Ivanov
Bulletin of Experimental Biology and Medicine|May 26, 2018
Immunochemical Diagnosis of Multiple MyelomaN V Lyubimova, Yu S Timofeev, V M Abaev, et al.
Klinicheskaia Laboratornaia Diagnostika|October 31, 2022
Biochemical profile of Bence-Jones type multiple myelomaNina Vasilyevna Lyubimova, Yu S Timofeev, V M Abaev, et al.
Bulletin of Experimental Biology and Medicine|March 10, 2020
Glial Fibrillary Acidic Protein in the Diagnosis and Prognosis of Malignant Glial TumorsN V Lyubimova, Yu S Timofeev, A A Mitrofanov, et al.
Bulletin of Experimental Biology and Medicine|August 12, 2014
Components of the RANK/RANKL/OPG system, IL-6, IL-8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumorsN E Kushlinskii, Yu S Timofeev, Yu N Solov'ev, et al.
Bulletin of Experimental Biology and Medicine|June 23, 2022
Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung CancerN V Lyubimova, A E Kuz'minov, A A Markovich, et al.
Klinicheskaia Laboratornaia Diagnostika|September 12, 2022
Chromogranin B in blood serum of patients with neuroendocrine tumorsNina Vasilyevna Lyubimova, Yu S Timofeev, A A Markovich, et al.
Bulletin of Experimental Biology and Medicine|August 31, 2017
Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone TumorsN E Kushlinskii, E S Gershtein, Yu N Solov'ev, et al.
Bulletin of Experimental Biology and Medicine|November 24, 2020
Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone TumorsN E Kushlinskii, A A Alferov, Yu S Timofeev, et al.
Klinicheskaia Laboratornaia Diagnostika|December 10, 2020
Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcomaNikolay Evgenievich Kushlinskii, A A Alferov, I V Boulytcheva, et al.
Pageof 1